Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10018282 | 0.91 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL10018274 | 0.82 | — | — | |
| SCHEMBL10050039 | 0.78 | ACHE (0.31) | TDP1ACHESMN1; SMN2 | |
| SCHEMBL10018267 | 0.77 | — | — | |
| SCHEMBL15634844 | 0.74 | CYP4F2 (0.35) | ACHESMN1; SMN2CYP4F2CYP4A11TSHR | |
| SCHEMBL10049881 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHR | |
| SCHEMBL20058601 | 0.71 | TDP1 (0.31) | TDP1 | |
| SCHEMBL12975284 | 0.71 | BRD4 (0.32) | — | |
| SCHEMBL991007 | 0.70 | ACHE (0.51) | TDP1ACHE | |
| SCHEMBL14458906 | 0.70 | ACHE (0.51) | TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142763-A1 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142763-A1 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142763-A1 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, NSUN2, DIS3 | TDP1 71/4885ACHE 4761/4885SMN1; SMN2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.